AbbVie (NYSE:ABBV) is ticking up; according to a new Samsung Bioepis report, Humira's U.S. market share stays above 70% even with increasing biosimilar competition.
Losing U.S. exclusivity in early 2023, Humira, the top-selling arthritis medication from AbbVie, let biosimilars from Amgen (NASDAQ:AMGN), Teva (NYSE:TEVA), and Pfizer (NYSE:PFE) onto the market. After factoring over a third of AbbVie's income in 2022, Humira's share fell to 27% in 2023.
Humira still dominated 96% of the market as of February 2024, but its share dropped to 77% in May after several pharmacy benefit managers, notably CVS Health (CVS), kicked it off important formularies.AbbVie has 72% of the adalimumab market as of November 2024; biosimilars are taking center stage, rising from 2% to 23% in a year. Humira is still the leading market participant even with the evolving rivalry.
https://finance.yahoo.com/news/humira-holds-firm-72-market-164134395.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.